ArticleJournal of experimental & clinical cancer research : CR2022

Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.

Ilaria Romito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.